大名城(600094.SH):約13.51億元競得上海青浦區房地產項目
格隆匯12月2日丨大名城(600094.SH)公佈,2021年12月2日,公司全資子公司名城地產(福建)有限公司(“受讓人”)經公開競投,獲得上海市青浦區規劃和自然資源局公開掛牌轉讓的位於上海青浦區一地塊。
地塊名稱:青浦區重固鎮郟店路南側44a-01地塊。四至範圍:東至崧卓路,南至河道,西至曹家宅路,北至郟店路。出讓方式:招掛複合。土地用途:普通商品房;出讓面積:42222.1平方米;容積率:2.0;出讓年限:普通商品房70年;最終競得價:人民幣135,111萬元。受讓人按要求配建保障性住房建築面積佔該地塊規劃總住宅建築面積5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.